Latest News
Regulatory Update
|
2 May 2013
0 Likes 
The UK’s cost containment agency, the National Institute for Health and Care Excellence (NICE), will soon begin to directly assist the National Health Service (NHS) with the use of innovative new
Read More...
Latest News
|
12 April 2013
0 Likes
Draft guidance issued yesterday by the UK’s cost containment agency, the National Institute for Health and Care Excellence (NICE), does not recommend reimbursement for Cell Therapeutics’ Pixuvri
Read More...
Latest News
Regulatory Update
|
10 April 2013
0 Likes
The UK cost containment agency, the National Institute for Health and Care Excellence (NICE), recommended on 9 April 2013 reimbursement for two in vitro diagnostic (IVD) devices for detecting
Read More...
Latest News
|
3 April 2013
0 Likes
Following the lead of Chinese and Korean regulatory authorities, NICE—formerly the National Institute of Health and Clinical Excellence—now has a new name to go with a new work program brought into
Read More...
Latest News
Regulatory Update
|
29 March 2013
0 Likes
The UK’s National Institute for Health and Clinical Excellence (NICE) will not recommend reimbursement for Pfizer’s new kidney cancer drug Inlyta (axitinib) as a result its comparison data, the agency
Read More...
Regulatory Update
|
28 March 2013
0 Likes
The UK’s cost containment agency, the National Institute for Health and Clinical Excellence (NICE), has recommended reimbursement for tobramycin (Tobi Podhaler, Novartis) and colistimethate sodium
Read More...
Latest News
|
28 March 2013
0 Likes
In draft guidance released on 27 March 2013, the UK’s National Institute for Health and Clinical Excellence (NICE) declined to recommend National Health Service coverage of Pfizer’s Xalkori
Read More...
Latest News
Regulatory Update
|
22 March 2013
0 Likes
The UK’s National Institute for Clinical Excellence (NICE) has opened a consultation on its draft medical technology guidance recommending National Health Service (NHS) coverage of a new device
Read More...
Latest News
Regulatory Update
|
21 March 2013
0 Likes
The UK’s cost containment agency, the National Institute of Health and Clinical Excellence (NICE), has issued its final appraisal determination recommending reimbursement by the National Health
Read More...
Regulatory Update
|
20 March 2013
0 Likes
In draft guidance released on 20 March 2013, the UK's National Institute for Health and Clinical Excellence (NICE) recommends against National Health Service (NHS) reimbursement for Novartis’ breast
Read More...